Gut microbiota consisting of 100 trillion intestinal microbes play a fundamental role in human health and disease. Unlike pharmaceuticals to be metabolized after its absorption, intestinal microbes with therapeutic efficacy, if identified successfully, are considered superior for its role as drug without being metabolized within human body. Consequently, the pharmabiotic approaches to identify and develop intestinal bacteria as the ideal therapeutics are being actively investigated with little success due to the challenges in the identification of the therapeutic strains.
We identified the natural Lactobacilli JBD strains removing fat effectively in the gut and commercialized as anti-obesity probiotics successfully. Moreover, we also identified the natural Lactobacilli strains removing ammonia in the gut. Further development and commercialization will provide the first probiotics that can lower brain ammonia concentration and thus have neuroprotection efficacy to the host.
Probiotics inhibiting Fat Absorption
Acts on Fat and Carbohydrates
Inherent Safety for the Whole Family
Fat is usually digested into fatty acids before the body absorbs it; however, not all fatty acids are absorbed into the body. Some fatty acids are used by gastrointestinal probiotics such as lactobacillus. JBD strains, the active ingredient of fat-blocker probiotics Ditenar®, are novel fat-absorbing probiotics with enhanced capacities for fatty acid absorption. Daily supplementation of JBD strains reduces fat absorption in the intestines, resulting in reduced caloric intake and possibly weight reduction of the person taking the supplement.
Strains having ability to inhibit obesity and pharmaceutical composition containing the same.